Cargando…

Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations

INTRODUCTION: Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margetić, Sandra, Ćelap, Ivana, Delić Brkljačić, Diana, Pavlović, Nikola, Šupraha Goreta, Sandra, Kobasić, Ivana, Lovrenčić-Huzjan, Arijana, Bašić Kes, Vanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Croatian Society of Medical Biochemistry and Laboratory Medicine 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904970/ https://www.ncbi.nlm.nih.gov/pubmed/31839722 http://dx.doi.org/10.11613/BM.2020.010702

Ejemplares similares

DOAC Dipstick Testing Can Reliably Exclude the Presence of Clinically Relevant DOAC Concentrations in Circulation
por: Margetić, Sandra, et al.
Publicado: (2022)

Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysers
por: Ćelap, Ivana, et al.
Publicado: (2020)

SIALORRHEA AND XEROSTOMIA IN PARKINSON’S DISEASE PATIENTS
por: Špiljak, Bruno, et al.
Publicado: (2022)

OPTIC NERVE SHEATH SONOGRAPHY IS A PROMISING TOOL FOR ASSESSMENT OF RAISED INTRACRANIAL PRESSURE IN PATIENTS ADMITTED TO NEUROLOGICAL INTENSIVE CARE UNIT
por: Lovrenčić-Huzjan, Arijana, et al.
Publicado: (2020)

EHMTI-0196. Tension type headache – the correlation between pain intensity, depressive symptoms and impairment of daily functions
por: Puretic, M Bosnar, et al.
Publicado: (2014)

Red Dress Day in Croatia: stroke prevention based on sex differences
por: Lovrenčić-Huzjan, Arijana, et al.
Publicado: (2020)

Recommendations for Management of Patients with Carotid Stenosis
por: Lovrencic-Huzjan, Arijana, et al.
Publicado: (2012)

Advanced Asymptomatic Carotid Disease and Cognitive Impairment: An Understated Link?
por: Martinić-Popović, Irena, et al.
Publicado: (2012)

Carotid Disease and Stroke
por: Lovrencic-Huzjan, Arijana, et al.
Publicado: (2012)

Prevalence of Chronic Headache in Croatia
por: Vuković-Cvetković, Vlasta, et al.
Publicado: (2013)

Measurement of rivaroxaban and apixaban in serum samples of patients
por: Harenberg, Job, et al.
Publicado: (2014)

Interference of M-protein on prothrombin time test – case report
por: Margetić, Sandra, et al.
Publicado: (2016)

SOCIOECONOMIC INFLUENCE OF TOBACCO USE AND DENTAL CARIES EXPERIENCE IN DIFFERENT MALE CROATIAN POPULATIONS
por: Badel, Tomislav, et al.
Publicado: (2018)

Apixaban/heparin/rivaroxaban: Melaena and thrombocytopenia: 2 case reports
Publicado: (2020)

Treatment of migraine and tension-type headache in Croatia
por: Vuković, Vlasta, et al.
Publicado: (2010)

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice
por: Pham, Phuong Tran, et al.
Publicado: (2019)

EVAULATION OF BLINK REFLEX BETWEEN PATIENTS WITH IDIOPATHIC TRIGEMINAL NEURALGIA AND HEALTHY VOLUNTEERS
por: Badel, Tomislav, et al.
Publicado: (2022)

Insights into complexity of congenital disorders of glycosylation
por: Goreta, Sandra Supraha, et al.
Publicado: (2012)

Hemispheric Asymmetry of Visual Cortical Response by Means of Functional Transcranial Doppler
por: Roje-Bedeković, Marina, et al.
Publicado: (2012)

Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial
por: Bhagirath, Vinai C., et al.
Publicado: (2017)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
por: Meihandoest, Tamana, et al.
Publicado: (2021)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Rivaroxaban Suppresses Atherosclerosis by Inhibiting FXa-Induced Macrophage M1 Polarization-Mediated Phenotypic Conversion of Vascular Smooth Muscle Cells
por: Ma, Yanpeng, et al.
Publicado: (2021)

Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?
por: Freyburger, Geneviève, et al.
Publicado: (2015)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
por: Kim, Paul Y., et al.
Publicado: (2018)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects
por: Ansell, Jack, et al.
Publicado: (2021)

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
por: Bradshaw, Paige Garber, et al.
Publicado: (2022)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
por: ASLAN, Onur, et al.
Publicado: (2022)

Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
por: Harenberg, Job, et al.
Publicado: (2011)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5eoheps3td6nhk9immib4rh43a